Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations

DSpace/Manakin Repository

Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations

Citable link to this page

 

 
Title: Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations
Author: Ajore, Ram; Raiser, David; McConkey, Marie; Jöud, Magnus; Boidol, Bernd; Mar, Brenton; Saksena, Gordon; Weinstock, David M; Armstrong, Scott; Ellis, Steven R; Ebert, Benjamin L; Nilsson, Björn

Note: Order does not necessarily reflect citation order of authors.

Citation: Ajore, R., D. Raiser, M. McConkey, M. Jöud, B. Boidol, B. Mar, G. Saksena, et al. 2017. “Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations.” EMBO Molecular Medicine 9 (4): 498-507. doi:10.15252/emmm.201606660. http://dx.doi.org/10.15252/emmm.201606660.
Full Text & Related Files:
Abstract: Abstract Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53‐intact tumors (P ≪ 10−10), and shRNA‐mediated knockdown of RPGs activated p53 in TP53‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically.
Published Version: doi:10.15252/emmm.201606660
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376749/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630491
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters